ADC Therapeutics is cutting 17% of its workforce and reorganizing the company to focus resources on its lead cancer drug Zynlonta.
The commercial-stage biotechnology company said Wednesday that the cuts are part of a reorganization following the completion of two of its trials this year, as well as to find operational efficiencies.
With the reduced workforce and organizational changes in place, ADC expects to turn its attention to its clinical, regulatory and manufacturing activities while supporting its drug Zynlonta, also known as loncastuximab tesirine-lpyl.
The company said it will maintain its full commercial and medical affairs footprint as it prepares for a pre-supplemental Biologics License Application meeting with the Food and Drug Administration in August and a planned supplemental filing in the fourth quarter.
ADC expects to save $10 million a year from the layoffs and broader reorganization, but will have to pay a one-time pretax charge of $3 million toward severance, benefits and other related costs.
The company said it expects to have enough cash runway to last at least until 2028.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
June 24, 2026 07:48 ET (11:48 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.